Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christopher A Eide

Showing results (71-80 of 83) with videos related to

Pageof 9
Sort By:
Investigational New Drugs|January 6, 2021
NT157, an IGF1R-IRS1/2 inhibitor, exhibits antineoplastic effects in pre-clinical models of chronic myeloid leukemiaRenata Scopim-Ribeiro, João Agostinho Machado-Neto, Christopher A Eide, et al.
Cancer Cell|July 18, 2006
Activating alleles of JAK3 in acute megakaryoblastic leukemiaDenise K Walters, Thomas Mercher, Ting-Lei Gu, et al.
Cancer Cell|September 24, 2019
Combining the Allosteric Inhibitor Asciminib with Ponatinib Suppresses Emergence of and Restores Efficacy against Highly Resistant BCR-ABL1 MutantsChristopher A Eide, Matthew S Zabriskie, Samantha L Savage Stevens, et al.
Blood|February 26, 2025
A CEBPB/IL-1β/TNF-α feedback loop drives drug resistance to venetoclax and MDM2 inhibitors in monocytic leukemiaBasil Allen, Daniel Bottomly, Thomas Köhnke, et al.
Nature Communications|January 18, 2019
Clinical resistance to crenolanib in acute myeloid leukemia due to diverse molecular mechanismsHaijiao Zhang, Samantha Savage, Anna Reister Schultz, et al.
Cancer Cell|November 3, 2009
AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistanceThomas O'Hare, William C Shakespeare, Xiaotian Zhu, et al.
Clinical and Translational Medicine|December 19, 2022
Loss of G0/G1 switch gene 2 (G0S2) promotes disease progression and drug resistance in chronic myeloid leukaemia (CML) by disrupting glycerophospholipid metabolismMayra A Gonzalez, Idaly M Olivas, Alfonso E Bencomo-Alvarez, et al.
Blood|August 2, 2019
Genomic landscape of neutrophilic leukemias of ambiguous diagnosisHaijiao Zhang, Beth Wilmot, Daniel Bottomly, et al.
Blood Cancer Discovery|May 21, 2025
Genetic and Phenotypic correlates of clinical outcomes with Venetoclax in Acute Myeloid Leukemia: The GEN-PHEN-VEN studyCurtis A Lachowiez, Mael Heiblig, Gaspar Aspas Requena, et al.
Blood Neoplasia|April 20, 2026
Results of a phase 1 trial testing ruxolitinib plus venetoclax in patients with relapsed/refractory acute myeloid leukemiaUma Borate, Cristina E Tognon, Yazan F Madanat, et al.
Pageof 9

Showing results (71-80 of 83) with videos related to

Sort By:
Pageof 9
Investigational New Drugs|January 6, 2021
NT157, an IGF1R-IRS1/2 inhibitor, exhibits antineoplastic effects in pre-clinical models of chronic myeloid leukemiaRenata Scopim-Ribeiro, João Agostinho Machado-Neto, Christopher A Eide, et al.
Cancer Cell|July 18, 2006
Activating alleles of JAK3 in acute megakaryoblastic leukemiaDenise K Walters, Thomas Mercher, Ting-Lei Gu, et al.
Cancer Cell|September 24, 2019
Combining the Allosteric Inhibitor Asciminib with Ponatinib Suppresses Emergence of and Restores Efficacy against Highly Resistant BCR-ABL1 MutantsChristopher A Eide, Matthew S Zabriskie, Samantha L Savage Stevens, et al.
Blood|February 26, 2025
A CEBPB/IL-1β/TNF-α feedback loop drives drug resistance to venetoclax and MDM2 inhibitors in monocytic leukemiaBasil Allen, Daniel Bottomly, Thomas Köhnke, et al.
Nature Communications|January 18, 2019
Clinical resistance to crenolanib in acute myeloid leukemia due to diverse molecular mechanismsHaijiao Zhang, Samantha Savage, Anna Reister Schultz, et al.
Cancer Cell|November 3, 2009
AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistanceThomas O'Hare, William C Shakespeare, Xiaotian Zhu, et al.
Clinical and Translational Medicine|December 19, 2022
Loss of G0/G1 switch gene 2 (G0S2) promotes disease progression and drug resistance in chronic myeloid leukaemia (CML) by disrupting glycerophospholipid metabolismMayra A Gonzalez, Idaly M Olivas, Alfonso E Bencomo-Alvarez, et al.
Blood|August 2, 2019
Genomic landscape of neutrophilic leukemias of ambiguous diagnosisHaijiao Zhang, Beth Wilmot, Daniel Bottomly, et al.
Blood Cancer Discovery|May 21, 2025
Genetic and Phenotypic correlates of clinical outcomes with Venetoclax in Acute Myeloid Leukemia: The GEN-PHEN-VEN studyCurtis A Lachowiez, Mael Heiblig, Gaspar Aspas Requena, et al.
Blood Neoplasia|April 20, 2026
Results of a phase 1 trial testing ruxolitinib plus venetoclax in patients with relapsed/refractory acute myeloid leukemiaUma Borate, Cristina E Tognon, Yazan F Madanat, et al.
Pageof 9